leadf
logo-loader
viewVerona Pharma

Verona Pharma has compound with 'massive potential to impact lives of COPD and asthma patients'

Verona Pharma PLC (LON:VRP) chairman David Ebsworth tells Proactive London's Andrew Scott the company's made 'massive progress' in the last few years.

''When we started it was really three or four people, we didn't have a  lot of money, we had early data and over the last five years we've raised significant capital, hired some excellent people to supplement the team and delivered a number of different clinical trials which have shown we have a compound that has massive potential to impact the lives of patients with COPD as well as with asthma or cystic fibrosis.''

''I'm actually quite disappointed in the current share price''.

''I think there's a massive upside.''.

''Since I joined the company as chairman I've probably spent £300k buying shares - £125k of that this year to demonstrate my belief in the company and our programme''.

Quick facts: Verona Pharma

Price: - -

AIM:VRP
Market: AIM
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Vox Royalties' snaps up Bushvelds' Brits Vanadium Project as second...

Proactive London's Ryan Long explains the strategy behind Vox Royalties' (CVE:VOX) acquiring royalty on Bushveld's Brits Vanadium Project. This is hot on the heels of the acquisition of a portfolio of royalties in North America earlier this month. The total consideration for the...

4 hours, 47 minutes ago

2 min read